BioAmber lost money every year it operated, the more it operated, the more it lost. Losing money every year, they were unable to get additional financing and the stock price tanked to where they couldn't raise money by selling stock, especially after they were delisted from exchanges in Canada and the US. They went bankrupt, couldn't reorganize, and were liquidated, and that occurred under the supervision and control of federal courts in Canada and the US. Everything was legal, above board, and well documented for anyone to read. Had the technology been as valuable as you've convinced yourself it was, one of the myriad of chemical and strategic finance companies would have paid more than what it sold for. It's what they do. But they didn't, so perhaps it wasn't so valuable.
LCYB bought the plant and patents for just north of $4M. That was the best bid from the 8 companies solicited, so that's what it was worth. After the purchase, LCYB invested another $20M or so to get the plant to run better, but then announced later they were going to make other products there as well. That's additional information about the value of the technology.
As a shareholder, you owned a piece of a company that went bankrupt. That company was obligated to service its debts and couldn't. When that happens, a bankruptcy court will sell everything the company owns and pay as much of the debt as they can, and the company ends. That's where you are now. Everything your stock without a ticker owned is gone, the corporation voided in the US and subsidiaries dissolved in Canada.
You made a terrible investment. That's just a fact.
Market Data 
Markets 
AI
